PMID- 21977031
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20111110
LR  - 20211020
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Print)
IS  - 1687-8450 (Linking)
VI  - 2011
DP  - 2011
TI  - Serum monocyte chemoattractant protein-1 in pancreatic cancer.
PG  - 518394
LID - 10.1155/2011/518394 [doi]
LID - 518394
AB  - Background/Aims. Pancreatic ductal adenocarcinoma (PDA) has etiological 
      association with chronic inflammation. Elevated circulating levels of 
      inflammatory mediators, such as monocyte chemoattractant protein-1 (MCP-1), are 
      found in obese individuals. We hypothesized that serum MCP-1 levels are elevated 
      in obese PDA patients. Methods. ELISA was used to analyze MCP-1 serum levels in 
      PDA (n = 62) and intraductal papillary mucinous neoplasms (IPMN) (n = 27). 
      Recursive partitioning statistical analysis investigated the relationship between 
      log MCP-1 and clinicopathological parameters. Results. Log MCP-1 values were 
      significantly (P < 0.05) elevated in patients with BMI >/= 37.5. In patients with 
      BMI < 37.5, average log MCP-1 values were significantly elevated in PDA patients 
      when compared to IPMN patients. Within the IPMN group, higher log MCP-1 levels 
      correlated with increased age. Recursive partitioning analysis of IPMN versus PDA 
      revealed a strategy of predicting characteristics of patients who are more likely 
      to have cancer. This strategy utilizes log MCP-1 as the primary factor and also 
      utilizes smoking status, gender, and age. Conclusion. MCP-1 is a promising 
      biomarker in pancreatic cancer. The potential of using MCP-1 to distinguish PDA 
      from IPMN patients must be studied in larger populations to validate and 
      demonstrate its eventual clinical utility.
FAU - Sullivan, Jennifer
AU  - Sullivan J
AD  - Department of Surgery and Jefferson Pancreatic, Biliary and Related Cancer 
      Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
FAU - Gong, Qiaoke
AU  - Gong Q
FAU - Hyslop, Terry
AU  - Hyslop T
FAU - Lavu, Harish
AU  - Lavu H
FAU - Chipitsyna, Galina
AU  - Chipitsyna G
FAU - Yeo, Charles J
AU  - Yeo CJ
FAU - Arafat, Hwyda A
AU  - Arafat HA
LA  - eng
GR  - R21 CA133753/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20111001
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC3184439
EDAT- 2011/10/07 06:00
MHDA- 2011/10/07 06:01
PMCR- 2011/10/01
CRDT- 2011/10/07 06:00
PHST- 2011/03/25 00:00 [received]
PHST- 2011/07/28 00:00 [revised]
PHST- 2011/08/02 00:00 [accepted]
PHST- 2011/10/07 06:00 [entrez]
PHST- 2011/10/07 06:00 [pubmed]
PHST- 2011/10/07 06:01 [medline]
PHST- 2011/10/01 00:00 [pmc-release]
AID - 10.1155/2011/518394 [doi]
PST - ppublish
SO  - J Oncol. 2011;2011:518394. doi: 10.1155/2011/518394. Epub 2011 Oct 1.